Long-term culture of human liver tissue with advanced hepatic functions.

A major challenge for studying authentic liver cell function and cell replacement therapies is that primary human hepatocytes rapidly lose their advanced function in conventional, 2-dimensional culture platforms. Here, we describe the fabrication of 3-dimensional hexagonally arrayed lobular human liver tissues inspired by the liver's natural architecture. The engineered liver tissues exhibit key features of advanced differentiation, such as human-specific cytochrome P450-mediated drug metabolism and the ability to support efficient infection with patient-derived inoculums of hepatitis C virus. The tissues permit the assessment of antiviral agents and maintain their advanced functions for over 5 months in culture. This extended functionality enabled the prediction of a fatal human-specific hepatotoxicity caused by fialuridine (FIAU), which had escaped detection by preclinical models and short-term clinical studies. The results obtained with the engineered human liver tissue in this study provide proof-of-concept determination of human-specific drug metabolism, demonstrate the ability to support infection with human hepatitis virus derived from an infected patient and subsequent antiviral drug testing against said infection, and facilitate detection of human-specific drug hepatotoxicity associated with late-onset liver failure. Looking forward, the scalability and biocompatibility of the scaffold are also ideal for future cell replacement therapeutic strategies.

[1]  G. Superti-Furga,et al.  Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection , 2013, Nature Medicine.

[2]  R. Gebhardt,et al.  Liver zonation: Novel aspects of its regulation and its impact on homeostasis. , 2014, World journal of gastroenterology.

[3]  Walker Inman,et al.  Liver tissue engineering in the evaluation of drug safety , 2009, Expert opinion on drug metabolism & toxicology.

[4]  E. Messersmith,et al.  Organ Donation and Utilization in the United States, 1999–2008 , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  Anthony Atala,et al.  Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function. , 2012, Biomaterials.

[6]  N. Fausto,et al.  Establishment, characterization, and long‐term maintenance of cultures of human fetal hepatocytes , 2003, Hepatology.

[7]  T. Nishimura,et al.  Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[8]  Ludovic Vallier,et al.  Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. , 2010, The Journal of clinical investigation.

[9]  Junmin Zhu,et al.  Bioactive modification of poly(ethylene glycol) hydrogels for tissue engineering. , 2010, Biomaterials.

[10]  Hitomi Shirahama,et al.  Phenotypic regulation of liver cells in a biofunctionalized three-dimensional hydrogel platform. , 2016, Integrative biology : quantitative biosciences from nano to macro.

[11]  O. B. Usta,et al.  Dynamic interplay of flow and collagen stabilizes primary hepatocytes culture in a microfluidic platform. , 2014, Lab on a chip.

[12]  F. Oesch,et al.  Hepatocytes cultured in alginate microspheres: an optimized technique to study enzyme induction. , 2005, Toxicology.

[13]  W. Marks,et al.  Organ donation and utilization in the United States, 2004 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  D. Hay,et al.  Liver tissue engineering and cell sources: issues and challenges , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[15]  R. Fontana,et al.  Mechanisms of drug-induced liver injury: from bedside to bench , 2011, Nature Reviews Gastroenterology &Hepatology.

[16]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[17]  Hitomi Shirahama,et al.  Biofunctionalized Hydrogel Microscaffolds Promote 3D Hepatic Sheet Morphology. , 2016, Macromolecular bioscience.

[18]  Nancy Cheng,et al.  Human hepatic stem cells from fetal and postnatal donors , 2007 .

[19]  Sangeeta N Bhatia,et al.  Modeling hepatitis C virus infection using human induced pluripotent stem cells , 2012, Proceedings of the National Academy of Sciences.

[20]  A. Iwama,et al.  Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells , 2003, Development.

[21]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[22]  Sangeeta N. Bhatia,et al.  Cell and tissue engineering for liver disease , 2014, Science Translational Medicine.

[23]  Won-Gun Koh,et al.  Biomimetic strain hardening in interpenetrating polymer network hydrogels , 2007 .

[24]  Takashi Aoi,et al.  Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells , 2012, Proceedings of the National Academy of Sciences.

[25]  Nobuko Uchida,et al.  Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells. , 2008, Tissue engineering. Part A.

[26]  Sangeeta N. Bhatia,et al.  Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures , 2010, Proceedings of the National Academy of Sciences.

[27]  O. B. Usta,et al.  Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells. , 2015, Tissue engineering. Part C, Methods.

[28]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[29]  T. Nishimura,et al.  Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing , 2014, PLoS medicine.

[30]  K. Tilmant,et al.  Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins , 2012, Cell Biology and Toxicology.

[31]  H. Yagi,et al.  Embryonic and induced pluripotent stem cells as a model for liver disease. , 2009, Critical reviews in biomedical engineering.

[32]  Juan Carlos Pérez-Mesa,et al.  Construct , 2020, Definitions.

[33]  Robin D. Hughes,et al.  Alginate Microencapsulated Hepatocytes Optimised for Transplantation in Acute Liver Failure , 2014, PloS one.

[34]  R. Taub Liver regeneration: from myth to mechanism , 2004, Nature Reviews Molecular Cell Biology.

[35]  Jeroen Rouwkema,et al.  Endothelial cells assemble into a 3-dimensional prevascular network in a bone tissue engineering construct. , 2006, Tissue engineering.

[36]  Yunfang Wang,et al.  Human hepatic stem cell and maturational liver lineage biology , 2011, Hepatology.

[37]  M. Otto,et al.  Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.

[38]  H. Conjeevaram,et al.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. , 1995, The New England journal of medicine.

[39]  I. Weissman,et al.  Efficient endoderm induction from human pluripotent stem cells by logically directing signals controlling lineage bifurcations. , 2014, Cell stem cell.

[40]  A milestone for hepatitis C virus research: a virus generated in cell culture is fully viable in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Y. Lai,et al.  Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1) , 2006, Journal of Biological Chemistry.